Want to see EXOZ full AI Analyst Report?
eXoZymes (EXOZ) AI Stock Analysis
eXoZymes
(NASDAQ:EXOZ)
The overall score of 40 reflects a high-risk, pre-revenue biotechnology company. The most significant factors are the weak financial performance, characterized by increasing losses and substantial cash burn, and the deeply bearish technical trend with the stock in oversold territory. The balance sheet stabilization provides a minor offset, but the company's future is heavily dependent on securing additional funding, which remains a critical risk.
eXoZymes (EXOZ) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $38.33M
- Dividend Yield
- ―
- Average Volume (3M)
- 8,531
- Price to Earnings (P/E)
- -3.4
- Beta (1Y)
- 1.35
- Revenue Growth
- ―
- EPS Growth
- -21.64%
- Country
- US
- Employees
- 32
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
eXoZymes Business Overview & Revenue Model
Company Description
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc...
How the Company Makes Money
null
eXoZymes Financial Statement Overview
Summary
Pre-revenue biotech with widening operating losses and significant negative free cash flow. The balance sheet has improved with positive equity and low leverage, but the declining asset base due to cash burn remains a major concern. Overall financial health is weak and dependent on securing additional financing.
Income Statement
10Very NegativeBalance Sheet
35NegativeCash Flow
20Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 68.61K | 0 | -267.38K | 0 | -147.75K | -59.41K |
| EBITDA | -10.51M | -8.98M | -5.59M | -1.80M | -1.18M | -1.15M |
| Net Income | -10.19M | -9.16M | -5.86M | -2.04M | -1.40M | -1.21M |
Balance Sheet | ||||||
| Total Assets | 7.98M | 5.97M | 13.03M | 3.56M | 2.69M | 2.35M |
| Cash, Cash Equivalents and Short-Term Investments | 5.65M | 3.04M | 9.72M | 66.53K | 558.57K | 547.81K |
| Total Debt | 1.09M | 1.24M | 1.39M | 1.61M | 608.77K | 720.63K |
| Total Liabilities | 4.33M | 2.57M | 2.61M | 3.94M | 1.31M | 1.15M |
| Stockholders Equity | 3.65M | 3.40M | 10.42M | -384.32K | 1.37M | 1.20M |
Cash Flow | ||||||
| Free Cash Flow | -7.14M | -6.67M | -8.90M | -1.47M | -1.44M | -2.01M |
| Operating Cash Flow | -7.00M | -6.50M | -8.51M | -1.18M | -1.26M | -1.59M |
| Investing Cash Flow | -145.90K | -150.22K | -359.22K | -311.17K | -87.21K | -312.25K |
| Financing Cash Flow | 5.81M | -27.71K | 18.52M | 1.00M | 1.36M | 2.31M |
eXoZymes Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EXOZ, the sentiment is Negative. The current price of 4.30 is below the 20-day moving average (MA) of 4.47, below the 50-day MA of 5.68, and below the 200-day MA of 7.76, indicating a bearish trend. The MACD of -0.49 indicates Negative momentum. The RSI at 36.26 is Neutral, neither overbought nor oversold. The STOCH value of 59.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EXOZ.
eXoZymes Risk Analysis
eXoZymes disclosed 47 risk factors in its most recent earnings report. eXoZymes reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RiskseXoZymes Peers Comparison
Overall Rating
BDRX48Neutral
NCEL42Neutral- EXOZ40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| BDRX | 48Neutral | $1.80M | -64.03 | -42.42% | ― | ― | 97.97% |
| NCEL | 42Neutral | $13.73M | 7.73 | 21.75% | ― | ― | ― |
| EXOZ | 40Underperform | $38.33M | -3.44 | -292.13% | ― | ― | -21.64% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| EXOZ | Exozymes Inc. | 4.52 | -8.98 | -66.52% | |
| BDRX | Biodexa Pharmaceuticals Plc | 2.80 | -213.20 | -98.70% | |
| ADTX | Aditxt, Inc. | 0.04 | -1123.16 | -100.00% | |
| NCEL | Newcelx Ltd. | 2.49 | -3.17 | -55.97% | |
| VRAX | Virax Biolabs Group Ltd. Class A | 1.10 | -11.65 | -91.37% |
eXoZymes Corporate Events
eXoZymes Highlights Investor Presentation for Capital Markets Outreach
PositiveOn October 6, 2026, eXoZymes Inc. prepared an investor presentation intended for distribution to investment bankers, offering participants, and existing and prospective investors. The document, filed as an exhibit, is designed to support the company&...
eXoZymes Sets Date for 2026 Shareholders Meeting
NeutraleXoZymes announced that it scheduled its 2026 annual meeting of shareholders for November 13, 2026, setting a formal timeline for its upcoming governance and voting activities. The company established September 15, 2026 as the record date to determin...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 16, 2026